CCL22 and colorectal carcinoma: More importantly, consistent with the requirement of GRP78 in assisting CRC 5-FU resistant, disruption of CCL17/CCL22-CCR4 signal axis by the antagonist or treatment of MK-2206 2HCI and IP3 all efficiently rescued 5-FU resistance of tumors cells as measured by both cell viability assay (Fig. 5E) and colony-formation assay (Fig. 5F).